Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations This work confirms the clinical utility of ctDNA for RAS/BRAF molecular testing to ...

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306). This is an ASCO Meeting Abstract ...

Cancer genomic profiling is rapidly transforming the clinical management of cancer patients. Results from our study indicate that metastatic colorectal cancer patients with certain BRAF mutations ...

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers. The first ...

Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies—one targeting epidermal growth factor receptor (EGFR), the other ...

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...

What is the best upfront chemotherapy option for patients with colorectal cancer (CRC) and unresectable liver metastases? A new report demonstrated why patients benefit most from starting on a ...

Amgen has signed up to help Biocartis get its RAS biomarker tests approved in the U.S. The pact positions Biocartis to register its Idylla RAS tests as companion diagnostics for Amgen's colorectal ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...